Benzo[a]pyrene and Caenorhabditis elegans: defining the genotoxic potential in an organism lacking the classical CYP1A1 pathway.
Animals
Benzo(a)pyrene
/ administration & dosage
Caenorhabditis elegans
/ drug effects
Caenorhabditis elegans Proteins
/ genetics
Comet Assay
Cytochrome P-450 CYP1A1
/ metabolism
Cytochrome P-450 Enzyme System
/ genetics
DNA Damage
/ drug effects
Disease Models, Animal
Dose-Response Relationship, Drug
Mutagenicity Tests
Mutagens
/ administration & dosage
Benzo[a]pyrene
Caenorhabditis elegans
DNA adducts
Xenobiotics
Journal
Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
21
07
2020
accepted:
22
12
2020
pubmed:
10
1
2021
medline:
28
10
2021
entrez:
9
1
2021
Statut:
ppublish
Résumé
Benzo[a]pyrene (BaP) is bioactivated in most organisms by the cytochrome P450 (CYP) enzymes, mainly CYP1A1, ultimately resulting in the reactive metabolite BaP-7,8-dihydrodiol-9,10-epoxide (BPDE) capable of covalently binding to DNA and forming adducts. This step has been defined as the key process in cancer initiation in humans. However, limited knowledge is available about the consequences of BaP exposure in organisms lacking this classical CYP1A1 pathway, one example is the model nematode Caenorhabditis elegans. The aim of this study was to define the genotoxic potential of BaP in C. elegans and to advance our understanding of xenobiotic processing in the absence of the CYP1A1 pathway. Exposure to high concentrations of BaP (0-40 µM) significantly affected life cycle endpoints of C. elegans, which were manifested by a reduced reproductive output and shortened life span. An optimised comet assay revealed that DNA damage increased in a dose-dependent manner; however, no bulky DNA adducts (dG-N
Identifiants
pubmed: 33420596
doi: 10.1007/s00204-020-02968-z
pii: 10.1007/s00204-020-02968-z
pmc: PMC7904753
doi:
Substances chimiques
CYP35 protein, C elegans
0
Caenorhabditis elegans Proteins
0
Mutagens
0
Benzo(a)pyrene
3417WMA06D
Cytochrome P-450 Enzyme System
9035-51-2
Cytochrome P-450 CYP1A1
EC 1.14.14.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1055-1069Références
Environ Mol Mutagen. 2016 Apr;57(3):229-35
pubmed: 26919089
J Toxicol Environ Health A. 2008;71(15):1043-50
pubmed: 18569613
Trends Cell Biol. 2013 Sep;23(9):409-20
pubmed: 23726168
Toxicol Sci. 2010 Dec;118(2):444-53
pubmed: 20864627
Carcinogenesis. 1991 Jul;12(7):1273-80
pubmed: 2070493
IARC Monogr Eval Carcinog Risks Hum. 2010;92:1-853
pubmed: 21141735
Toxicol Lett. 2004 Jan 15;146(2):151-8
pubmed: 14643967
Hum Mol Genet. 2000 Apr 12;9(6):869-77
pubmed: 10767309
J Cell Sci. 2003 Dec 15;116(Pt 24):4965-75
pubmed: 14625390
Environ Sci Pollut Res Int. 2018 Jan;25(3):2879-2888
pubmed: 29143265
Drug Metab Dispos. 1997 May;25(5):617-22
pubmed: 9152602
Chem Res Toxicol. 1993 May-Jun;6(3):356-63
pubmed: 7686408
Genome Res. 2014 Oct;24(10):1624-36
pubmed: 25030888
Comp Biochem Physiol C Toxicol Pharmacol. 2014 Mar;160:75-85
pubmed: 24333255
Arch Biochem Biophys. 2001 Nov 15;395(2):158-68
pubmed: 11697852
Nat Protoc. 2007;2(11):2772-81
pubmed: 18007613
Drug Metab Dispos. 2020 Mar;48(3):160-168
pubmed: 31836608
Pharmacol Rep. 2015 Oct;67(5):996-1009
pubmed: 26398396
Mutat Res. 2010 Feb;696(1):55-61
pubmed: 20026424
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt E):1-538
pubmed: 23193840
Biochem Biophys Rep. 2015 Jun 25;2:172-178
pubmed: 29124160
Front Pharmacol. 2011 Mar 18;2:12
pubmed: 21687507
J Biochem Mol Toxicol. 2017 Jul;31(7):
pubmed: 28111842
J Biochem Mol Toxicol. 2011 Sep-Oct;25(5):269-79
pubmed: 21308896
Sci Rep. 2018 Sep 6;8(1):13333
pubmed: 30190484
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
Toxicol Lett. 2012 Sep 3;213(2):160-6
pubmed: 22759596
Chem Res Toxicol. 2014 Nov 17;27(11):1901-17
pubmed: 25279998
Drug Metab Pharmacokinet. 2006 Aug;21(4):257-76
pubmed: 16946553
Genetics. 2006 Nov;174(3):1173-87
pubmed: 16980394
Sci Total Environ. 2008 Aug 1;400(1-3):142-61
pubmed: 18817948
Nucl Receptor Res. 2015;2:
pubmed: 27478824
Environ Health Perspect. 1985 Dec;64:69-84
pubmed: 3830701
J Pharmacol Exp Ther. 2017 May;361(2):199-208
pubmed: 28228532
Drug Metab Dispos. 2010 Apr;38(4):617-25
pubmed: 20056724
Science. 2003 Jun 20;300(5627):1921
pubmed: 12817143
Mutat Res. 1999 Jul 15;443(1-2):139-47
pubmed: 10415437
Nat Commun. 2020 May 1;11(1):2169
pubmed: 32358516
Drug Metab Dispos. 2006 Jun;34(6):943-9
pubmed: 16510539
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
Chem Res Toxicol. 2013 Oct 21;26(10):1570-8
pubmed: 24047243
J Mol Biol. 2007 Jun 29;370(1):1-13
pubmed: 17499272
Environ Toxicol Pharmacol. 2016 Jul;45:356-61
pubmed: 27389785
Ecotoxicol Environ Saf. 2007 Mar;66(3):378-83
pubmed: 16618507
FASEB J. 2001 Mar;15(3):627-34
pubmed: 11259381
J Mol Biol. 2004 Aug 20;341(4):951-59
pubmed: 15328611
Nature. 2008 Nov 6;456(7218):53-9
pubmed: 18987734
Mech Ageing Dev. 2005 Mar;126(3):381-7
pubmed: 15664624
Genome Res. 2000 May;10(5):703-13
pubmed: 10810093
Cell. 2019 May 2;177(4):821-836.e16
pubmed: 30982602
Toxicology. 2018 Apr 1;398-399:1-12
pubmed: 29471073
Chem Res Toxicol. 1995 Jan-Feb;8(1):136-42
pubmed: 7703357
Toxicol Appl Pharmacol. 2005 Aug 1;206(1):73-93
pubmed: 15963346
J Toxicol Environ Health A. 2009;72(19):1168-80
pubmed: 20077185
ScientificWorldJournal. 2014;2014:920398
pubmed: 24895670
Mol Biol Evol. 1998 Nov;15(11):1447-59
pubmed: 12572608
BMC Genomics. 2013 Mar 12;14:164
pubmed: 23496871
Chem Res Toxicol. 1996 Oct-Nov;9(7):1113-6
pubmed: 8902265
Cancer Res. 1992 Apr 1;52(7):1868-74
pubmed: 1551116
Arch Toxicol. 2018 Apr;92(4):1625-1638
pubmed: 29368147
Toxicology. 1996 May 17;109(2-3):119-27
pubmed: 8658543
Arch Biochem Biophys. 2005 Jun 1;438(1):93-102
pubmed: 15910738
J Exp Zool A Comp Exp Biol. 2006 Sep 1;305(9):720-30
pubmed: 16902959
Carcinogenesis. 2008 Mar;29(3):656-65
pubmed: 18204078
Chem Res Toxicol. 2001 Feb;14(2):192-201
pubmed: 11258968
Nat Rev Drug Discov. 2006 May;5(5):387-98
pubmed: 16672925